Enfrentando la enfermedad de Alzheimer en los países en desarrollo.
Rev Neuropsiquiatr 80 (2), 2017 (P. 105-110)
Recibido: 03/02/2017 Aceptado: 12/06/2017
This Review summarizes many of the persistent biological alterations associated with childhood maltreatment including changes in neuroendocrine and neurotransmitter systems and pro-inflammatory cytokines in addition to specific alterations in brain areas associated with mood regulation. Finally, I d...iscuss several candidate gene polymorphisms that interact with childhood maltreatment to modulate vulnerability to major depression and PTSD and epigenetic mechanisms thought to transduce environmental stressors into disease vulnerability.
Neuron Review, vol. 89, March 2, 2016 pp.892-909
more
The principle of “the best interest of the child” should guide decisions by politicians whenever
children are affected. This is one of the basic ideas in the UN Convention on the Rights
of the Child. Decision makers should assess the consequences for children before taking
action. Today, this... principle is not fully respected in European countries in relation to migrant
children.
more
Bull World Health Organ 2013;91:773–783 | doi: http://dx.doi.org/10.2471/BLT.13.118422
(Submitted: 15 February 2013 – Revised version received: 21 June 2013 – Accepted: 22 June 2013 – Published online: 20 August 2013)
SCOPING QUESTION: In adults with acute convulsive seizures, where intravenous access is available, which first-line anti- epileptic medication should be used to abort seizures when compared to comparator?
Q5: What is the added advantage of doing an electroencephalography (EEG) in people with convulsive epilepsy in non- specialist settings in low and middle income countries?
Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?
SCOPING QUESTION: For adults and children with medication-resistant convulsive epilepsy, which anti-epileptic medications produce benefits and/or harm in the specified outcomes when compared to a placebo or a comparator?
Материалы научно-практической конференции с международным участием «Достижения в нейробиологии и терапии болезни Альцгеймера», посвященной памяти профессора Э..... Штернберга (Москва, 6 декабря 2013 г.)
more
This brief draws out some recommendations for Ebola response actors in North Kivu. It includes lessons learned primarily from (i) historical outbreaks in Congo; (ii) outbreaks in Uganda in 2000-01 and 2012; (iii) the 2014-2016 West African epidemic; (iv) the outbreak in Equateur Province in DRC (May...- July 2018), and (v) the ongoing outbreak in North Kivu and Ituri Provinces in DRC (August 2018 - ongoing). The full report can be accessed here: https://opendocs.ids.ac.uk/opendocs/handle/123456789/14160.
more
Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Report for WHO Meningitis guideline revision
Dr Thomas Waite, April 2014
Field Epidemiology Services, Public Health England; UK
Guide technique pour la prise en charge des maladies cardiovasculaires dans le cadre des soins de santé primaires
The Open AIDS Journal, 2012, 6, 245-258
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more